Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. develops clinical-stage biotechnology programs for cancer and rare diseases. Company news centers on TARA-002, an investigational cell-based therapy being studied for non-muscle invasive bladder cancer and lymphatic malformations, including updates from the ADVANCED-2 trial in BCG-Unresponsive and BCG-Naïve NMIBC patient groups.
Recurring updates also cover IV Choline Chloride, an investigational phospholipid substrate replacement therapy for patients receiving long-term parenteral support. Other company announcements include clinical-conference presentations, FDA designation updates, financial results, equity compensation grants under Nasdaq rules, and capital-raising activity tied to Protara's development-stage pipeline.
Protara Therapeutics, Inc. (Nasdaq: TARA) will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2021, at 12:25 PM ET. The presentation will be accessible through a webcast on the Company's website and archived for 90 days post-event. Protara focuses on developing transformative therapies for cancer and rare diseases, including its lead program TARA-002 for non-muscle invasive bladder cancer and IV Choline Chloride for intestinal failure-associated liver disease.
Protara Therapeutics (TARA) announced a study revealing that approximately 30% of patients dependent on parenteral nutrition (PN) experience cholestasis, a key pathology of intestinal failure-associated liver disease (IFALD). This highlights an unmet medical need for effective treatments. The company is developing IV Choline Chloride as a replacement therapy for choline deficiency in PN patients, with promising results from prior studies. Protara's ongoing research aims to further investigate IFALD and assess the prevalence of choline deficiency among affected patients.
Protara Therapeutics, Inc. (Nasdaq: TARA) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, occurring virtually from September 13-15, 2021. The company's prerecorded presentation will be available on September 13, 2021, at 7:00am ET, accessible via the Events and Presentations section on their website. Protara focuses on developing therapies for cancer and rare diseases, including TARA-002 for bladder cancer and lymphatic malformations, as well as IV Choline Chloride for intestinal failure-associated liver disease.
Protara Therapeutics, Inc. (TARA) reported significant progress in developing TARA-002 for non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). As of June 30, 2021, the company holds $145 million in cash and investments. They completed IND-enabling studies and are on track to submit an IND application by year-end, aiming to initiate a Phase 1 trial for NMIBC. However, R&D expenses rose to $5.9 million, contributing to a net loss of $12.8 million for Q2 2021, compared to a $7.1 million loss in Q2 2020.
Protara Therapeutics (Nasdaq: TARA) announced management will present at the Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 10:00am ET. This virtual event will allow participants to gain insights into Protara's pipeline, including TARA-002, a cell-based therapy aimed at treating non-muscle invasive bladder cancer and lymphatic malformations.
The presentation will be available via webcast on the company's website, archived for 90 days for investor access.
Protara Therapeutics (Nasdaq: TARA) welcomed Dr. Jane Huang to its Board of Directors, bringing extensive experience in oncology drug development. Dr. Huang's leadership roles include Chief Medical Officer at BeiGene and key positions at Acerta Pharma and Genentech. The appointment aims to enhance Protara's progress in developing TARA-002, a therapy for non-muscle invasive bladder cancer and lymphatic malformations. This move is expected to strengthen Protara's strategic direction as they continue to advance their innovative therapies for cancer and rare diseases.
Protara Therapeutics (Nasdaq: TARA) has announced its participation in two significant virtual investor conferences. The first is the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021, at 11:35 AM ET, followed by the Jefferies Virtual Healthcare Conference on June 2, 2021, at 1:30 PM ET. Investors can access live webcasts of the presentations on the Company's website, which will be archived for 90 days. Protara focuses on developing therapies for cancer and rare diseases, including its lead program, TARA-002.
Protara Therapeutics (TARA) provided a business update and financial results for Q1 2021, highlighting strong cash reserves of $155 million as of March 31, 2021. The company is on track to file an Investigational New Drug (IND) application and initiate a Phase 1 trial for TARA-002 targeting non-muscle invasive bladder cancer (NMIBC) by year-end 2021. The research and development expenses rose 125% to $7 million due to costs related to TARA-002, while general administrative expenses decreased. Protara reported a net loss of $13.5 million or $1.20 per share.
Protara Therapeutics (Nasdaq: TARA) announced plans for an additional clinical study to support their Biologics License Application for TARA-002, targeting Lymphatic Malformations (LMs). Based on FDA feedback, the company will conduct large-scale GMP manufacturing comparability in late 2021 and initiate a pediatric clinical study pending alignment with the FDA. TARA-002 is derived from the same cell bank as OK-432, an approved treatment in Japan and Taiwan. Protara aims to deliver the first FDA-approved drug for LMs.
Protara Therapeutics (Nasdaq: TARA) has granted inducement non-qualified stock options for 120,000 shares to Dr. Martín Sebastian Olivo, the new Chief Medical Officer. The options have an exercise price of $15.30 per share, aligning with Protara's closing price as of April 19, 2021. Vesting occurs over four years, with 25% vesting after one year and the remainder vesting monthly. This award, approved by the Compensation Committee, aligns with NASDAQ Listing Rule 5635(c)(4). Protara is focused on developing therapies for cancer and rare diseases.